Positive Results from GSK's DREAMM-8 Phase III Trial for Blenrep in Multiple Myeloma
Thursday, 7 March 2024, 10:23
Positive Milestone for GSK's Blenrep Combo Therapy
GSK has announced positive results from the DREAMM-8 phase III trial for Blenrep in the treatment of relapsed/refractory multiple myeloma. The trial has shown extended progression-free survival, emphasizing the potential of this therapy in improving patient outcomes.
Promising Results for Patients
The success of the Blenrep combo therapy is a significant step in the advancement of treatment options for multiple myeloma patients. It underscores GSK's commitment to developing innovative therapies to address unmet medical needs in oncology.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.